ADC Therapeutics Aktie
| 1,97USD | -0,01USD | -0,51% |
WKN DE: A2PSR8 / ISIN: CH0499880968
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 80,50 |
| Redmile Group LLC | 16,21 |
| Redmile Group LLC | 16,21 |
| Thomas Pfisterer | 10,12 |
| Prosight Management LP | 9,97 |
| Prosight Management LP | 9,96 |
| OrbiMed Advisors LLC | 4,69 |
| OrbiMed Advisors Private Equity | 4,69 |
| AstraZeneca PLC | 4,15 |
| Oaktree Capital Management LP | 4,15 |
| Sio Capital Management LLC | 3,41 |
| BlackRock Fund Advisors | 3,10 |
| Morgan Stanley Capital Services LLC | 2,90 |
| Auven Therapeutics Management LLLP | 2,33 |
| iShares Russell 2000 ETF | 2,07 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 127 | 208 | 312 | 317 | 162 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,00 | 0,11 | 0,66 | 0,43 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 123 | 450 | 525 | 446 | 336 |
| Summe Anlagevermögen | 15 | 63 | 93 | 83 | 18 |
| Summe Aktiva | 138 | 514 | 618 | 529 | 355 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 5 | 115 | 140 | 117 | 124 |
| Summe Fremdkapital | 27 | 178 | 452 | 440 | 503 |
| Summe Eigenkapital | 111 | 336 | 166 | 89 | -148 |
| Summe Passiva | 138 | 514 | 618 | 529 | 355 |
Adresse
| Biopôle, 1066 Epalinges | |
| Telefon | +41 (212) 653-02-00 |
| Internet | http://www.adctherapeutics.com |
Management
|
Ameet Mallik
President, Chief Executive Officer & Director |
|
David S. Ege
Chief Technical Officer |
|
Jean Pierre Bizzari
Independent Non-Executive Director |
|
Jose Carmona
Chief Financial Officer |
|
Kimberly Pope
Chief People Officer |
|
Kristen Harrington-Smith
Chief Commercial Officer & Senior Vice President |
|
Mohamed Zaki
Chief Medical Officer |
|
Nicole Riley
Head-Investor Relation |
|
Patrick van Berkel
Chief Scientific Officer |
|
Peter Hug
Vice Chairman |
|
Peter J. Graham
Secretary & Chief Legal Officer |
|
Robert W. Azelby
Independent Non-Executive Director |
|
Ron Squarer
Chairman |
|
Thomas Pfisterer
Non-Executive Director |
|
Tyrell J. Rivers
Independent Non-Executive Director |
|
Victor Sandor
Independent Non-Executive Director |
|
Viviane Monges
Independent Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
